Myriad Genetics: (NASD: MYGN)
$32.93
-0.20 (-0.60%)
Volume 1,685,179
04:00 PM ET
Zacks Rank: 2-Buy 
BROKERAGE REPORTS
0 items in cart
MYRIAD GENETICS [MYGN]
Reports for Purchase
Showing records 1 - 20 ( 36 total )
|
Price: 24.95
|
|
Price: 24.95
|
|
Price: 24.95
|
|
Price: 24.95
|
|
Price: 24.95
|
|
Company: MYRIAD GENETICS Industry: MED-BIOMED/GENE Terminating Coverage Due to Analyst Departure. Provider: Dougherty and Company, LLC.
Price: 10.00
|
|
Price: 24.95
|
|
Price: 24.95
|
|
Company: MYRIAD GENETICS Industry: MED-BIOMED/GENE MYGN: CMS Releases Preliminary Payment Methodology Continued Uncertainty for BRACAnalysis Reimbursement Until at Least November, Maintain NEUTRAL Provider: Dougherty and Company, LLC. Analyst: HUSAIN J
Price: 25.00 |
|
Company: MYRIAD GENETICS Industry: MED-BIOMED/GENE MYGN: CMS Releases Preliminary Payment Methodology Continued Uncertainty for BRACAnalysis Reimbursement Until at Least November, Maintain NEUTRAL Provider: Dougherty and Company, LLC. Analyst: HUSAIN J
Price: 25.00 |
|
Price: 24.95
|
|
Company: MYRIAD GENETICS Industry: MED-BIOMED/GENE MYGN: Drawing a Line in the Sand for FY13 Guidance Provider: Dougherty and Company, LLC. Analyst: HUSAIN J
Price: 25.00 |
|
Company: MYRIAD GENETICS Industry: MED-BIOMED/GENE MYGN: 2013 Reimbursement Uncertainty for BRACAnalysis Takes Us to the Sidelines Downgrading to NEUTRAL Provider: Dougherty and Company, LLC.
Price: 25.00
|
|
Company: MYRIAD GENETICS Industry: MED-BIOMED/GENE MYGN: BRACAnalysis Reimbursement is on the Lab Schedule, Which is a Positive But No Clarity on the 2013 Rates Until September 28th Provider: Dougherty and Company, LLC.
Price: 25.00
|
|
Company: MYRIAD GENETICS Industry: MED-BIOMED/GENE Medical Technology: Thoughts on Our Medical Technology Universe Heading Into the Dog Days of Summer Provider: Dougherty and Company, LLC.
Price: 25.00
|
|
Price: 24.95
|
|
Company: MYRIAD GENETICS Industry: MED-BIOMED/GENE MYGN: Solid Numbers in F3Q:12 Provider: Dougherty and Company, LLC.
Price: 25.00
|
|
Company: MYRIAD GENETICS Industry: MED-BIOMED/GENE MYGN: Supreme Court in Conference Today, Decision on Whether They Hear ACLU Case Expected Monday 10 AM Thoughts From Our IP Expert Provider: Dougherty and Company, LLC.
Price: 25.00
|
|
Company: MYRIAD GENETICS Industry: MED-BIOMED/GENE MYGN: Mayo v. Prometheus Decision Overblown Reiterate MYGN Buy Provider: Dougherty and Company, LLC.
Price: 25.00
|
|
Company: MYRIAD GENETICS Industry: MED-BIOMED/GENE MYGN: Steady BRACAnalysis Business, Intl. Opportunities Pending, New Products Over the Horizon Initiating with a BUY Rating Provider: Dougherty and Company, LLC.
Price: 25.00
|
